MRSA vaccine

[Guest guest]

So do we know where and in whom this vaccine will be studied? Hopefully it would be those at highest risk--MSMs, esp HIV+ MSM. Perhaps our friends in ECAB have a better idea, and can help advocate for studies in the appropriate patient populations?

Jeff in Palm Springs

Date: Thu Dec 17, 2009 5:11 pm ((PST))Sanofi-aventis buys rights to Syntiron's MRSA vaccine by Dennis firstwordSanofi-aventis reported Wednesday that its vaccines unit, Sanofi Pasteur, entered into an exclusive global agreement for the rights to Syntiron’s vaccine designed to prevent Staphylococcus infections, including methicillin-resistant Staphylococcus aureas. Financial details were not disclosed.Under the agreed terms, Sanofi Pasteur will support the early development of the vaccine, and be responsible for all later development, regulatory approval and marketing. Sanofi Pasteur CEO Wayne Pisano noted that the deal is in line with the unit's "interest in partnering with biotechs to produce innovative vaccines."Yesterday, the vaccines unit announced that it was expanding its Phase II clinical study of a vaccine against Clostridium difficile infection. Reference Articles Sanofi purchases rights to Syntiron’s MRSA vaccine - (Bloomberg) Sanofi-aventis: licence pour un vaccin contre les infections à staphylocoque - (Le Matin) Sanofi Pasteur obtains license from Syntiron to develop and commercialize vaccine to prevent staphylococcus infections - (sanofi-aventis)

[Guest guest]

I sent this article out and the drug company just acquired the vaccine so i think its early and i think the company is beginning to plan developmentSent from my Verizon Wireless BlackBerryFrom: rolyatffej@...Date: Fri, 18 Dec 2009 12:54:15 EST< >Subject: MRSA vaccineSo do we know where and in whom this vaccine will be studied? Hopefully it would be those at highest risk--MSMs, esp HIV+ MSM. Perhaps our friends in ECAB have a better idea, and can help advocate for studies in the appropriate patient populations? Jeff in Palm Springs Date: Thu Dec 17, 2009 5:11 pm ((PST))Sanofi-aventis buys rights to Syntiron's MRSA vaccine by Dennis firstwordSanofi-aventis reported Wednesday that its vaccines unit, Sanofi Pasteur, entered into an exclusive global agreement for the rights to Syntiron’s vaccine designed to prevent Staphylococcus infections, including methicillin-resistant Staphylococcus aureas. Financial details were not disclosed.Under the agreed terms, Sanofi Pasteur will support the early development of the vaccine, and be responsible for all later development, regulatory approval and marketing. Sanofi Pasteur CEO Wayne Pisano noted that the deal is in line with the unit's "interest in partnering with biotechs to produce innovative vaccines."Yesterday, the vaccines unit announced that it was expanding its Phase II clinical study of a vaccine against Clostridium difficile infection. Reference Articles Sanofi purchases rights to Syntiron’s MRSA vaccine - (Bloomberg) Sanofi-aventis: licence pour un vaccin contre les infections à staphylocoque - (Le Matin) Sanofi Pasteur obtains license from Syntiron to develop and commercialize vaccine to prevent staphylococcus infections - (sanofi-aventis)